The ZNF304-integrin axis protects against anoikis in cancer

Nature Communications

Volumn 6, Issue , 2015, Pages

  Aslan, Burcu ^a,b   Monroig, Paloma ^a,b,c   Hsu, Ming Chuan ^a,d   Pena, Guillermo Armaiz ^a   Rodriguez Aguayo, Cristian ^a   Gonzalez Villasana, Vianey ^a   Rupaimoole, Rajesha ^a,b   Nagaraja, Archana Sidalaghatta ^a,b   Mangala, Selanere ^a   Han, Hee Dong ^e   Yuca, Erkan ^a   Wu, Sherry Y ^a   Ivan, Cristina ^a   Moss, Tyler J ^a   Ram, Prahlad T ^a   Wang, Huamin ^a   Gol Chambers, Alexandra ^a   Ozkayar, Ozgur ^a,f   Kanlikilicer, Pinar ^a   Fuentes Mattei, Enrique ^a   Kahraman, Nermin ^a   Pradeep, Sunila ^a   Ozpolat, Bulent ^a   Tucker, Susan ^a   Hung, Mien Chie ^a,g   Baggerly, Keith ^a   Bartholomeusz, Geoffrey ^a   Calin, George ^a   Sood, Anil K ^a   Lopez Berestein, Gabriel ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e Konkuk University School of Medicine   (South Korea)

^f HACETTEPE UNIVERSITY   (Turkey)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; FOCAL ADHESION KINASE; INTEGRIN; MESSENGER RNA; NANOPARTICLE; PACLITAXEL; PAXILLIN; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ZNF304; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; BETA INTEGRIN; TRANSCRIPTION FACTOR; ZNF304 PROTEIN, HUMAN;

APOPTOSIS; CANCER; CELLS AND CELL COMPONENTS; CYTOLOGY; DATA SET; DETECTION METHOD; GENE EXPRESSION; GENOME; INTEGRATED APPROACH; MODEL TEST; PROTEIN; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOIKIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CANCER PATIENT; CARCINOGENESIS; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE DELIVERY SYSTEM; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SINGLE DRUG DOSE; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR INVASION; CARCINOMA; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ANOIKIS; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INTEGRIN BETA CHAINS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 84935895247     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8351     Document Type: Article

References (66)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
2. Naora, H. & Montell, D. J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev. Cancer 5, 355-366 (2005).
3. Kipps, E., Tan, D. S. & Kaye, S. B. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat. Rev. Cancer 13, 273-282 (2013).
4. Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719-725 (2011).
5. Tadepally, H. D., Burger, G. & Aubry, M. Evolution of C2H2-zinc finger genes and subfamilies in mammals: species-specific duplication and loss of clusters, genes and effector domains. BMC Evol. Biol. 8, 176 (2008).
6. Serra, R. W., Fang, M., Park, S. M., Hutchinson, L. & Green, M. R. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. Elife 3, e02313 (2014).
7. Suyama, K., Shapiro, I., Guttman, M. & Hazan, R. B. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2, 301-314 (2002).
8. Abdul Azis, T. in: Qatar Foundation Annual Research Conference (2013) doi:10.5339/qfarf.2013.BIOP-0135.
9. Bowen, N. J. et al. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med. Genomics 2, 71 (2009).
10. Casey, T. et al. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res. Treat. 114, 47-62 (2009).
11. Persikov, A. V., Osada, R. & Singh, M. Predicting DNA recognition by Cys2His2 zinc finger proteins. Bioinformatics 25, 22-29 (2009).
12. Vachon, P. H. Integrin signaling, cell survival, and anoikis: distinctions, differences, and differentiation. J Signal Transduct. 2011, 738137 (2011).
13. Sood, A. K. et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J. Clin. Invest. 120, 1515 (2010).
14. Lu, C. et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18, 185-197 (2010).
15. Schnell, M. A., Hardy, C., Hawley, M., Propert, K. J. & Wilson, J. M. Effect of blood collection technique in mice on clinical pathology parameters. Hum. Gene Ther. 13, 155-161 (2002).
16. Carlson, T. R., Hu, H., Braren, R., Kim, Y. H. & Wang, R. A. Cell-autonomous requirement for β1 integrin in endothelial cell adhesion, migration and survival during angiogenesis in mice. Development 135, 2193-2202 (2008).
17. Weis, S. M. & Cheresh, D. A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nature Med. 17, 1359-1370 (2011).
18. Leung, C. S. et al. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat. Commun. 5, 5092 (2014).
19. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22 (2010).
20. Margadant, C., Monsuur, H. N., Norman, J. C. & Sonnenberg, A. Mechanisms of integrin activation and trafficking. Curr. Opin. Cell Biol. 23, 607-614 (2011).
21. Caccavari, F., Valdembri, D., Sandri, C., Bussolino, F. & Serini, G. Integrin signaling and lung cancer. Cell Adh. Migr. 4, 124 (2010).
22. Guo, W. & Giancotti, F. G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5, 816-826 (2004).
23. Grzesiak, J. J. et al. Knockdown of the β1 integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. Int. J. Cancer 129, 2905-2915 (2011).
24. Mitra, A. et al. Ligand-independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis. Oncogene 30, 1566-1576 (2011).
25. Minton, K. Cell adhesion: Integrating the integrin response. Nat. Rev. Mol. Cell Biol. 14, 401-401 (2013).
26. Schiller, H. B. et al. β1-and αv-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments. Nat. Cell Biol. 15, 625-636 (2013).
27. Barkan, D. & Chambers, A. F. β1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin. Cancer Res. 17, 7219-7223 (2011).
28. Jahangiri, A., Aghi, M. K. & Carbonell, W. S. β1 Integrin: critical path to antiangiogenic therapy resistance and beyond. Cancer Res. 74, 3-7 (2014).
29. Brakebusch, C. & Fässler, R. β 1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev. 24, 403-411 (2005).
30. Giancotti, F. G. Complexity and specificity of integrin signalling. Nat. Cell Biol. 2, E13-E14 (2000).
31. Zhang, Z., Vuori, K., Wang, H.-G., Reed, J. C. & Ruoslahti, E. Integrin activation by R-ras. Cell 85, 61-69 (1996).
32. Hughes, P. E. et al. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88, 521-530 (1997).
33. Kinbara, K., Goldfinger, L. E., Hansen, M., Chou, F.-L. & Ginsberg, M. H. Ras GTPases: integrins' friends or foes? Nat. Rev. Mol. Cell Biol. 4, 767-778 (2003).
34. Caswell, P. T. et al. Rab25 associates with α5β1 integrin to promote invasive migration in 3D microenvironments. Dev. Cell 13, 496-510 (2007).
35. Pasapera, A. M., Schneider, I. C., Rericha, E., Schlaepfer, D. D. & Waterman, C. M. Myosin II activity regulates vinculin recruitment to focal adhesions through FAK-mediated paxillin phosphorylation. J. Cell Biol. 188, 877-890 (2010).
36. Shibue, T. & Weinberg, R. A. Integrin β1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc. Natl Acad. Sci. USA 106, 10290-10295 (2009).
37. Morello, V. et al. β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 30, 4087-4096 (2011).
38. Lau, M.-T., So, W.-K. & Leung, P. C. Integrin β1 mediates epithelial growth factor-induced invasion in human ovarian cancer cells. Cancer Lett. 320, 198-204 (2012).
39. Petrás, M. et al. Molecular interactions of ErbB1 (EGFR) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance. Neuro Oncol. 15, 1027-1040 (2013).
40. Frisch, S. M. & Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124, 619-626 (1994).
41. Kim, Y.-N., Koo, K. H., Sung, J. Y., Yun, U.-J. & Kim, H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int. J. Cell Biol. 2012, 306879 (2012).
42. Simpson, C. D., Anyiwe, K. & Schimmer, A. D. Anoikis resistance and tumor metastasis. Cancer Lett. 272, 177-185 (2008).
43. Jenning, S., Pham, T., Kale Ireland, S., Ruoslahti, E. & Biliran, H. Bit1 in anoikis resistance and tumor metastasis. Cancer Lett. 333, 147-151 (2013).
44. Sakamoto, S., Schwarze, S. & Kyprianou, N. Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma. Eur. Urol. 59, 734-744 (2011).
45. Reginato, M. J. et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat. Cell Biol. 5, 733-740 (2003).
46. Sakamoto, S., McCann, R. O., Dhir, R. & Kyprianou, N. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res. 70, 1885-1895 (2010).
47. Frisch, S. M. & Ruoslahti, E. Integrins and anoikis. Curr. Opin. Cell Biol. 9, 701-706 (1997).
48. Frisch, S. M. & Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13, 555-562 (2001).
49. Lee, Y.-C. et al. Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol. Cancer Res. 11, 405-417 (2013).
50. Han, H. D. et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin. Cancer Res. 16, 3910-3922 (2010).
51. Kamat, A. A. et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 67, 281-288 (2007).
52. Lu, C. et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin. Cancer Res. 13, 4209-4217 (2007).
53. Lu, C. et al. Gene alterations identified by expression profiling in tumorassociated endothelial cells from invasive ovarian carcinoma. Cancer Res. 67, 1757-1768 (2007).
54. Sood, A. K. et al. Molecular determinants of ovarian cancer plasticity. Am. J. Pathol. 158, 1279-1288 (2001).
55. Thaker, P. H. et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancer Res. 10, 5145-5150 (2004).
56. Landen, C. N. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
57. Halder, J. et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12, 4916-4924 (2006).
58. Spannuth, W. A. et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int. J. Cancer 124, 1045-1053 (2009).
59. Kim, H.-S. et al. Functional roles of Src and Fgr in ovarian carcinoma. Clin. Cancer Res. 17, 1713-1721 (2011).
60. Tibes, R. et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512-2521 (2006).
61. Landen, C. N. et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther. 9, 3186-3199 (2010).
62. Cheema, S. K. et al. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J. Biol. Chem. 278, 19995-20005 (2003).
63. Lu, C. et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am. J. Obstet. Gynecol. 198, 477. e471-477. e410 (2008).
64. Landen, C. N. et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J. Natl Cancer Inst. 98, 1558-1570 (2006).
65. Langley, R. R. et al. Tissue-specific microvascular endothelial cell lines from H-2Kb-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res. 63, 2971-2976 (2003).
66. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B (Methodol.) 57, 289-300 (1995).